* If you want to update the article please login/register
"Angiotensin receptor blocker drugs can reprogramm CAFs to a quiescent state," the researchers say, but it is unknown if ARBs can boost immune responses to cancer. We developed safer ARBs here by chemically linking them to a polymer that degrades selectively in solid tumors' slightly acidic microenvironment, but not in tumor-free environments. ".
"The antibody guides the enzyme to the cancer cells, the enzyme cuts the sugars, and then the antibody directs immune cells to destroy the desialylated cancer cells. " Compared to the antibody alone, the conjugate enhanced tumor cell killing. Editing the cancer cell glycocalyx with an antibody-enzyme conjugate is a promising approach to cancer immune therapy.
"Immunotherapy has a great ability to cure cancer and prevent future relapse by stimulating the immune system to detect and destroy cancer cells. " Despite their promise, more research is required to determine how and why certain cancers fail to respond to immunotherapy and identify which therapeutic approaches, or combinations thereof, are most appropriate for each patient. ".
"The heterogeneous quality of cancer research across various areas of the primary tumor, across metastatic centers, time, and patients makes developing such a successful therapy difficult. " Here we provide a platform for investigating this robustness issue using patient response data from a sample population. We discovered a robust therapeutic protocol that incorporates oncolytic viruses with an immunotherapeutic vaccine as a result of this investigation.
"Immunotherapy has revolutionized cancer care, but an estimated 87% of patients currently do not receive long-term benefit from immune checkpoint blocker monotherapy. " To raise the response rates in patients who are immune to immune checkpoint inhibition, new therapeutic methods are required. ".
"The idea of combining a vaccine with immune checkpoint inhibitors has been widely studied in cancer management, but the complete response rate for this program is still unresolved. " We describe a genetically engineered cell membrane nanovesicle that integrates antigen self-presentation and immunosuppression for cancer immunotherapy. This work describes a highly effective vaccine regimen that can stimulate both native T cells and exhausted T cells, as well as a general approach to personalized cancer immunotherapy.
"Oncolytic virotherapy is a new form of immunotherapy that stimulates anti-tumor responses by selective self-replication within cancer cells and oncolytic virus-mediated immunostimulation. " Notably, talimogene laherparepvec, the Amgen company's first FDA-approved OV drug to be administered by intratumoral injection, is the first FDA-approved OV treatment for OVT therapy, and has been the most effective OVT therapy. "Once but not least, the future prospects and challenges of OVT are also discussed, with the intention of assisting medical researchers to more effectively use the OVT in cancer therapy. ".
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions